Hepatitis C - SciClone Reports Results From First ZADAXIN Phase 3 Hepatitis C Trial

SciClone Reports Results From First ZADAXIN Phase 3 Hepatitis C Trial
[Press Release] Market Wire via Yahoo! Finance - Dec 14 3:30 AM
SciClone Pharmaceuticals, Inc. today announced top-line results from the first of its two phase 3 clinical trials using ZADAXIN in combination with pegylated interferon alpha to treat patients with hepatitis C virus who have failed previous interferon-based therapy. Treatment with ZADAXIN and pegylated interferon alpha did not demonstrate a statistically significant benefit compared to Save to My Web

Viral Hepatitis Conference to Take Place February 27-28, 2006 in Boston, MA
RedNova - Jan 05 8:20 AM
BOSTON, Jan. 5 /PRNewswire/ -- Chronic hepatitis C (HCV) and B (HBV) are the most common causes of chronic viral hepatitis in the United States, posing serious risks for long-term medical complications, especially if left untreated.Save to My Web

Medivir Takes Its First Pharmaceutical Project Into Phase III and Sharpens Its Strategic Focus; Labial Herpes Project
FinanzNachrichten - Dec 22 12:18 AM
The US Food and Drug Administration (FDA) in an End-of-Phase-II Meeting has recently approved Medivir's proposal for configuring the pivotal clinical trials to allow drug registration of labial (oral) herpes project ME-609.Save to My Web

Auto sales jump 13% in Apr-Nov
The Economic Times - Dec 18 7:54 PM
Domestic auto sales grew 12.9% during the Apr-Nov 05 period, compared to the same period last year.Save to My Web